Celcuity (FRA:7VR) Total Liabilities: €308.49 Mil (As of Mar. 2026)


FRA:7VR Celcuity Inc FRA:7VR
11 GF Score
Price €87.00
! 2 Warning Signs
View Full Analysis

What is Celcuity Total Liabilities?

Celcuity FRA:7VR -1.14% 11 Total Liabilities is €308.49 Mil as of Mar. 2026. GuruFocus rates FRA:7VR with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Celcuity's Total Liabilities for the quarter that ended in Mar. 2026 was €308.49 Mil.

Celcuity's quarterly Total Liabilities increased from Sep. 2025 (€305.90 Mil) to Dec. 2025 (€312.57 Mil) but then declined from Dec. 2025 (€312.57 Mil) to Mar. 2026 (€308.49 Mil).

Celcuity's annual Total Liabilities increased from Dec. 2023 (€47.18 Mil) to Dec. 2024 (€123.68 Mil) and increased from Dec. 2024 (€123.68 Mil) to Dec. 2025 (€312.57 Mil).

Celcuity Total Liabilities Historical Data

* Premium members only.

The historical data trend for Celcuity's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celcuity Total Liabilities Chart

Celcuity Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.22 39.58 47.18 123.68 312.57

Celcuity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121.60 120.70 305.90 312.57 308.49
FRA:7VR
11GF Score
Celcuity Inc FRA:7VR
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celcuity Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Celcuity's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=37.706+(274.861+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=312.57

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=398.441-85.874
=312.57

Celcuity's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=28.728+(279.765+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=308.49

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=354.792-46.299
=308.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €308.49 Mil mean?
Celcuity (FRA:7VR) has a Total Liabilities of €308.49 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Celcuity and its competitors.
Is Celcuity's Total Liabilities too high?
Celcuity's current Total Liabilities is €308.49 Mil. Overall, Celcuity has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's Total Liabilities compare to ERAS and TNGX?
Celcuity's Total Liabilities of €308.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Celcuity and its competitors. Celcuity's current Total Liabilities is €308.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current Total Liabilities of €308.49 Mil. The current Total Liabilities is €308.49 Mil. Celcuity's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current Total Liabilities is €308.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celcuity Business Description

Other Exchanges CELC:USA
Address 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
11GF Score

Get the complete analysis for FRA:7VR

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€87.00
Price